{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:15:24Z","timestamp":1788830124594,"version":"build-2803163510"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/bor.0000000000000206","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T15:38:21Z","timestamp":1435937901000},"page":"505-510","source":"Crossref","is-referenced-by-count":33,"title":["Advances in the treatment of polyarticular juvenile idiopathic arthritis"],"prefix":"10.1097","volume":"27","author":[{"given":"Kate","family":"Webb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"R2-13-20210128","first-page":"1","article-title":"The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.","volume":"0","author":"Guzman","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R3-13-20210128","first-page":"1405","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis Arthritis R","volume":"66","author":"Nigrovic","year":"2014","journal-title":"heumatol"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of Treatment Strategies in Early Rheumatoid ArthritisA Randomized Trial.","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/art.21389","article-title":"Patterns of clinical remission in select categories of juvenile idiopathic arthritis.","volume":"52","author":"Wallace","year":"2005","journal-title":"Arthritis Rheumatism"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis.","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3899\/jrheum.131503","article-title":"Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.","volume":"41","author":"Wallace","year":"2014","journal-title":"J Rheumatol"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.24087","article-title":"Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.","volume":"61","author":"Albers","year":"2009","journal-title":"Arthritis Care Res"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score.","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","article-title":"Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis.","volume":"72","author":"McErlane","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","article-title":"Management of juvenile idiopathic arthritis: hitting the target.","volume":"11","author":"Hinze","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/acr.22259","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis.","volume":"66","author":"Ringold","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1546-0096-11-5","article-title":"Time to share.","volume":"11","author":"Wulffraat","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"R22-13-20210128","first-page":"1","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.","volume":"0","author":"Brunner","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3899\/jrheum.090442","article-title":"Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.","volume":"37","author":"Mease","year":"2010","journal-title":"J Rheumatol"},{"key":"R24-13-20210128","first-page":"Cd007356","article-title":"Rituximab for rheumatoid arthritis.","volume":"1","author":"Lopez-Olivo","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ard.2008.092106","article-title":"Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.","volume":"68","author":"Narvaez","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/RHU.0b013e3181ba3c6f","article-title":"Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists.","volume":"15","author":"Feito","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1586\/1744666X.2014.918847","article-title":"Intravenous golimumab in rheumatoid arthritis.","volume":"10","author":"Cohen","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1002\/art.38569","article-title":"A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results.","volume":"66","author":"Brunner","year":"2014","journal-title":"Arthritis Rheum"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-015-0516-6","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.","volume":"17","author":"Smolen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R33-13-20210128","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.","volume":"74","author":"Deodhar","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-B pathways.","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/ken501","article-title":"Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series.","volume":"48","author":"Karaderi","year":"2009","journal-title":"Rheumatology"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R42-13-20210128","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R43-13-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"R44-13-20210128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"R45-13-20210128","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-1223 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological antitumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R47-13-20210128","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R48-13-20210128","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","article-title":"Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.","volume":"36","author":"Kaur","year":"2014","journal-title":"Clin Ther"},{"key":"R49-13-20210128","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"R50-13-20210128","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis.","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"R51-13-20210128","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study.","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R52-13-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"Engl J Med"},{"key":"R53-13-20210128","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1408607","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis.","volume":"371","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"R54-13-20210128","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690550 versus placebo.","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R56-13-20210128","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA"},{"key":"R57-13-20210128","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2010.146191","article-title":"Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.","volume":"70","author":"Hinks","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R58-13-20210128","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/rheumatology\/ket152","article-title":"A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP814 protein.","volume":"52","author":"Moncrieffe","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R59-13-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/tpj.2014.3","article-title":"Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.","volume":"14","author":"Cobb","year":"2014","journal-title":"Pharmacogenom J"},{"key":"R60-13-20210128","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","article-title":"Prediction of clinical nonresponse to methotrexate treatment in juvenile idiopathic arthritis.","volume":"71","author":"Bulatovic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R61-13-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/FPC.0b013e32833f2cd0","article-title":"Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.","volume":"20","author":"Moncrieffe","year":"2010","journal-title":"Pharmacogenet Genom"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:34:04Z","timestamp":1620948844000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201509000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000206","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}